The relative mRNA level of glycolytic genes showed that combination treatment considerably suppressed HK2 and GPI expression in the xenograft tumor tissues (Figure S3), indicating an in vivo inhibitory effect of ponatinib and sirolimus on tumor metabolism. The gene discussed is HK2; the disease is neoplasm.